5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro.
;
Takaya Sakura;
Yasuteru Sakurai;
Yohei Kurosaki;
Daniel Ken Inaoka;
Norifumi Shioda;
Chris Smith ;
Jiro Yasuda;
Kouichi Morita;
Kiyoshi Kita;
(2022)
5-Aminolevulinic acid antiviral efficacy against SARS-CoV-2 omicron variant in vitro.
Tropical medicine and health, 50 (1).
30-.
ISSN 1348-8945
DOI: 10.1186/s41182-022-00422-7
The coronavirus disease 2019 (COVID 19) pandemic continues to pose a threat to global health. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has spread rapidly worldwide and became dominant in many countries. A natural 5-aminolevulinic acid (5-ALA) with sodium ferrous citrate (SFC) has demonstrated antiviral activity in Wuhan, Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 infections in vitro. In this study, we report antiviral activity of 5-ALA, 5-ALA with SFC led to IC50 of 329 and 765/191, respectively after infection with Omicron variant of SARS-CoV-2 in vitro. Our finding suggests that 5-ALA could be used as antiviral drug candidate to treat Omicron variant infected patients.
-
picture_as_pdf - 22.04.27 ALA Omicron (TMAH).pdf
-
subject - Published Version
-
- Available under Creative Commons: 4.0